Table 1.
Patient demographics, laboratory, preoperative diagnosis and modality for CBD diagnosis
| Total | OUH | NEMC | p value | |
|---|---|---|---|---|
| Total number of patients, n | 201 | 94 | 107 | |
| Patient demographics | ||||
| Female gender, n (%) | 134 (67%) | 59 (63%) | 75 (70%) | 0.27 |
| Age (mean ± SD) | 55 ± 19 | 51 ± 35 | 58 ± 20 | 0.05 |
| ASA class (median, [LQ, UQ]) | 2 [1, 2] | 2 [1, 2] | N/A | − |
| CCI score (median, [LQ, UQ]) | 2 [1, 4] | 2 [1, 4] | 3 [1, 4] | 0.05 |
| Laboratory markers | ||||
| White blood count, 109/L (mean ± SD) | 9.4 ± 4.1 | 9.6 ± 4.6 | 9.1 ± 3.6 | 0.40 |
| CRP, mg/L (mean ± SD) | 41 ± 71 | 36 ± 72 | 45 ± 70 | 0.40 |
| AST, µkat/L (mean ± SD) | 4.3 ± 3.8 | 5.3 ± 4.2 | 3.4 ± 3.1 | 0.001 |
| ALP, µkat/L (mean ± SD) | 3.5 ± 2.3 | 3.4 ± 2.1 | 3.6 ± 2.5 | 0.52 |
| Bilirubin, µmol/L (mean ± SD) | 54 ± 39 | 51 ± 35 | 56 ± 42 | 0.30 |
| Lipase, µkat/L (mean ± SD) | 14 ± 24 | 16 ± 25 | 10 ± 22 | 0.12 |
| Preoperative diagnosis | ||||
| Cholecystolithiasis, n (%) | 93 (46%) | 81 (86%) | 12 (11%) | 0.17 |
| Acute cholecystitis, n (%) | 61 (30%) | 36 (38%) | 25 (23%) | < 0.001 |
| Gallstone pancreatitis, n (%) | 40 (20%) | 23 (25%) | 17 (16%) | < 0.001 |
| Cholangitis, n (%) | 9 (5%) | 5 (5%) | 4 (4%) | 0.74** |
| Verified preoperative CBD stone | ||||
| Verified CBD stone, n (%) | 177 (88%) | 70 (74%) | 107 (98%) | < 0.001 |
| Not verified CBD stone, n (%) | 24 (12%) | 24 (26%) | 0 | – |
| Modality for CBD stone verification | ||||
| Ultrasound, n (%) | 92 (46%) | 16 (17%) | 78 (73%) | |
| MRCP, n (%) | 46 (23%) | 46 (49%) | N/A | |
| CT, n (%) | 36 (18%) | 7 (7%) | 29 (27%) | |
| CBDS confirmed on IOC, n (%) | 94 (47%) | 94(100%) | N/A | |
LQ lower quartile, UQ upper quartile, CCI Charleson’s comorbidity index, CBD common bile duct, MRCP magnetic resonance cholangio-pancreatography, CT computer tomography, IOC intraoperative cholangiography
**Fisher exat test, two sided p value